Endocrinology, Vol 133, 1462-1465, Copyright © 1993 by Endocrine Society

ARTICLES

Potentiation of insulin-like growth factor-I (IGF-I) activity by an antibody: supportive evidence for enhancement of IGF-I bioavailability in vivo by IGF binding proteins

CE Stewart, PC Bates, TA Calder, SM Woodall and JM Pell
Department of Molecular & Cellular Physiology, AFRC Institute of Animal Physiology and Genetics Research, Babraham, Cambridge, UK.

The effects of ovine polyclonal antibodies raised against human recombinant IGF-I were investigated in GH-deficient rodents in vivo both in the presence and absence of exogenous IGF-I. Dwarf mice (negligible endogenous serum IGF-I) treated with anti-IGF-I serum which had been pre-incubated with IGF-I exhibited a significantly greater rate of daily weight gain than did mice treated with the same dose of IGF-I alone (P < 0.001) or even a 2.5-fold higher dose (P < 0.001). Similar increases in whole body weight gain were observed in dwarf rats, with a concomitant increase in dissected muscle weight. Serum IGF- I concentrations were greater in all animals treated with the complex of anti-IGF-I antibodies and IGF-I than in those administered only IGF- I. Size exclusion chromatography of dwarf rat serum indicated the presence of high mol wt material (> 160 kDa) capable of binding 125I- IGF-I in the anti-IGF-I treated rats. We suggest that this particular polyclonal antibody is behaving in a similar manner to an enhancing IGF binding protein, maintaining a reservoir of bioactive IGF-I. Since the antibody has a slightly lower affinity (2 x 10(8) liters/M) than that of the type 1 receptor, these data provide tentative indirect evidence to support the hypothesis that the recently discovered mechanisms which apparently decrease the affinities of several IGFBPs may indeed result in increased IGF-I bioavailability.

This article has been cited by other articles:

				Y. Ning, A. G. P. Schuller, S. Bradshaw, P. Rotwein, T. Ludwig, J. Frystyk, and J. E. Pintar Diminished Growth and Enhanced Glucose Metabolism in Triple Knockout Mice Containing Mutations of Insulin-Like Growth Factor Binding Protein-3, -4, and -5 Mol. Endocrinol., September 1, 2006; 20(9): 2173 - 2186. [Abstract] [Full Text] [PDF]

				M. J. Fedele, C. H. Lang, and P. A. Farrell Immunization against IGF-I prevents increases in protein synthesis in diabetic rats after resistance exercise Am J Physiol Endocrinol Metab, June 1, 2001; 280(6): E877 - E885. [Abstract] [Full Text] [PDF]

				D. R. Clemmons, A. C. Moses, M. J. McKay, A. Sommer, D. M. Rosen, and J. Ruckle The Combination of Insulin-Like Growth Factor I and Insulin-Like Growth Factor-Binding Protein-3 Reduces Insulin Requirements in Insulin-Dependent Type 1 Diabetes: Evidence for in VivoBiological Activity J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1518 - 1524. [Abstract] [Full Text]

				J. M. Pell, R. A. Hill, C. E. H. Stewart, C. R. Weston, and H. C. Flick-Smith Enhancement of Insulin-Like Growth Factor I Activity by Novel Antisera: Potential Structure/Function Interactions Endocrinology, February 1, 2000; 141(2): 741 - 751. [Abstract] [Full Text] [PDF]

				R. A. Hill and J. M. Pell Regulation of Insulin-Like Growth Factor I (IGF-I) Bioactivity in Vivo: Further Characterization of an IGF-I-Enhancing Antibody Endocrinology, March 1, 1998; 139(3): 1278 - 1287. [Abstract] [Full Text] [PDF]

				S. Manes, L. Kremer, J. P. Albar, C. Mark, R. Llopis, and C. Martinez-A Functional Epitope Mapping of Insulin-Like Growth Factor I (IGF-I) by Anti-IGF-I Monoclonal Antibodies Endocrinology, March 1, 1997; 138(3): 905 - 915. [Abstract] [Full Text] [PDF]